Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk localized, muscle-invasive disease, according to a new editorial.

Recent advances in bladder cancer treatments may offer hope of curative care to more patients, including those with high-risk ...

Astellas said in a results update this morning that Padcev (enfortumab vedotin) will now bring in JPY 400 to 500 billion ($2.7 to $3.4 billion) on the back of the EV-302 study showing that the ...

and Seagen and Astellas’ Nectin-4-targeting ADC Padcev (enfortumab vedotin), which showed that the duo reduced the risk of death by 53% compared to chemotherapy when used as a first-line ...

When combined with chemotherapy and new drug formulations, like the antibody-drug conjugate enfortumab vedotin, which the FDA approved in 2019 for the treatment of advanced bladder cancer, these ...